PODD— AI Stock Forecast & Price Targets
Published 7/9/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live PODD price forecast →
PODD combines genuinely strong operating fundamentals (71% gross margins, 32% TTM sales growth, 23% ROE) with a stock that has been cut nearly in half YTD (-44.6%) and now sits near 52-week lows at $157. The setup is a classic quality-on-sale candidate, but a fresh FDA Class I recall, a pending Aug 5 earnings print, and the desk's history of systematically over-optimistic targets on this name argue for a measured accumulation rather than a chase.
Do not chase into the Aug 5 earnings print — that is the binary event and the sole legitimate near-term catalyst. Prefer either (a) a starter position at current $157 sized at ~1/3 of intended weight with hard stop below $138.79 (52-week low), or (b) waiting for post-earnings clarity. If earnings beat and guide firm, chase strength into $180-195. If they disappoint or the recall bleeds into guidance, $138 breaks and $120 opens up. Earnings is BOTH catalyst and invalidation.
1-6 month base case: post-earnings normalization with the stock re-rating into the $180-210 zone as the market digests the recall and confirms growth durability. This implies +15% to +33% from current. Bull case ($240+) requires a clean beat, raised guide, and evidence the recall is contained. Bear case ($120-130) requires either a guide-down or expanded recall scope. Mind changer: any additional FDA action, or a Q2 revenue miss materially below the $770M+ implied run-rate.
1-3 year thesis is intact: Omnipod 5 is the dominant tubeless AID platform, international expansion (Spain now, further EU markets to follow) is the next leg of TAM growth, and Type 2 diabetes indication expansion is the platform bet. If the company sustains 20%+ EPS growth, a forward P/E of 22-25x on out-year EPS of $10-12 supports $220-300 in 2-3 years. Structural risk: a superior tubeless competitor (Tandem Mobi, or a novel entrant) capturing the pharmacy channel, or CMS/PBM reimbursement changes compressing per-pod economics.
The underlying business is executing well. Q1 2026 revenue of $761.7M grew from $649.1M in Q2 2025 (a clean acceleration sequence: 649→706→784→762), with TTM Y/Y sales growth of 31.9% and Q/Q of 33.9%. Gross margin has held in a tight 69-72% band, and operating margin recovered to 16.0% in Q1 26 after a soft Q2 25. Net income of $91.1M in Q1 26 produced a 12.0% net margin. Cash flow quality is real — FCF of $86M in Q1 26 and $253M TTM operating cash flow of $619M. Balance sheet is manageable: $480M cash vs $948M debt, current ratio 2.49, debt/equity 0.73. ROE of 23% and ROIC of 13.6% are healthy for a med-tech. What's broken is not the P&L — it's the multiple: trailing P/E 36.7x, P/B 8.4x, EV/EBITDA 18.2x. Forward P/E of 19.5x and PEG of 0.73 look reasonable IF the 26.9% five-year EPS growth estimate holds, but the stock is being priced as if that consensus is at risk.
The tape is ugly across every timeframe. Weekly chart shows a collapse from ~$340 in early Q1 to $145-160, roughly a 55% drawdown from the 52-week high of $354.88. Daily chart confirms a persistent downtrend since May with price now stabilizing in a $140-165 base. Hourly shows constructive short-term action — price ($157) is above the SMA20 (+3.2%) and SMA50 (+1.7%), but still -35.8% below the SMA200, so this is a bounce inside a broken trend, not a trend change. RSI at 52 is neutral. The model's forecast bands are aggressive: 1h shows $197, 4h shows $290, 1d shows $245, 1wk shows $285 — but critically, the 1wk directional accuracy (50%) is BELOW the 78% naive baseline, so that upside band should be heavily discounted. The realistic technical read is: base $140-165, first resistance $180-195, then a gap zone into $220. 52-week low of $138.79 is the line in the sand.
Signal: Deutsche Bank initiated Buy with a $190 target (June 23), Insulet launched Omnipod 5 in Spain (a low-AID-penetration, high-CGM-adoption market — genuinely additive), and Zacks flagged setup for another earnings beat. Balancing that, Evercore ISI CUT its target from $200 to $180 (still Outperform) on July 6, and the FDA classified an Omnipod pod recall as Class I after 24 serious injury reports — this is the most important negative catalyst and directly explains part of the drawdown. The 8-K from June 25 disclosed an executive change alongside Reg FD/guidance items, which markets often treat cautiously. Consensus target of $236.65 vs $157 price implies +50% upside, but analyst targets on this name have been chronically too high — recent cuts (Evercore to $180) are more indicative of where the buy-side is actually anchoring.
- Omnipod 5 international rollout — Spain launch announced July 7, targeting a market with high CGM adoption but low AID penetration
- Sequential revenue acceleration from $649M (Q2 25) to $762M (Q1 26), demonstrating the platform is still gaining share
- PEG of 0.73 and consensus 5-yr EPS growth of 26.9% suggest earnings compounding is still front-loaded
- Deutsche Bank Buy initiation (June 23) frames PODD as the dominant tubeless AID player — a durable competitive moat
- Q1 26 EPS Q/Q growth of 158.5% and EPS/Sales surprise history of 18.5%/4.4% support setup for another beat on Aug 5
- FDA Class I recall of Omnipod pods linked to 24 serious injuries — most severe classification, direct product liability and warranty exposure
- Trailing P/E 36.7x and P/B 8.4x remain rich against a stock down 44.6% YTD — multiple compression is not finished if growth decelerates
- Evercore cut PT to $180 from $200 on July 6 — sell-side sentiment is deteriorating even among bulls
- Congressional insider (Tina Smith, spouse) sold $200-500K across two tranches in late April/early May, immediately preceding the drawdown
- Aug 5 earnings is a binary event — history of 18% EPS surprises cuts both ways; a miss on the recall-impacted quarter could break $138 support
- SMA200 sits -35.8% above spot, meaning the primary long-term trend is still firmly bearish — bounces have failed repeatedly on this name
- Prior calls on this name have systematically overshot on upside targets (+36% avg from live) — desk-level calibration warns against extrapolating the model's $245-290 forecasts
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord